
Please try another search
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Name | Age | Since | Title |
---|---|---|---|
William K. Heiden | 65 | 2015 | Independent Director |
Pascal Touchon | 61 | 2019 | Chairman of the Board |
Maria Grazia Roncarolo | 71 | 2020 | Independent Director |
Gregory Austin Ciongoli | - | 2024 | Independent Director |
Anhco Nguyen | 52 | 2021 | President, CEO & Director |
Carol G. Gallagher | 60 | 2013 | Lead Independent Director |
Matthew K. Fust | 60 | 2014 | Independent Director |
Ameet Mallik | 52 | 2021 | Independent Director |
Nachi Subramanian | - | 2025 | Director |
Zuie-Chin Huang | 59 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review